The authors report the results of a retrospective study conducted in an effort to define the results and risks of transsphenoidal surgery for patients whose prior therapy had failed. In a series of 1210 patients undergoing transsphenoidal surgery during a 10-year period, t 58 had received prior therapy: 127 for pituitary adenoma, 20 for craniopharyngioma, and 11 for other lesions. Prior therapy was considered "direct" when it consisted of craniotomy or transsphenoidal surgery (either open or stereotaxic), and "indirect" when it consisted of radiation therapy, adrenalectomy, or bromocriptine therapy. The current transsphenoidal operation was performed for persistent hyperfunctioning endocrinopathy in 63 patients, for visual loss in 72 patients, and for cerebrospinal fluid (CSF) rhinorrhea in 21 patients. Success rates were as follows: normalization of endocrinopathy was achieved in 35% of cases; improvement or stabilization of vision in 59%; and successful repair of CSF rhinorrhea in 74%. The risks associated with repeat transsphenoidal surgery are significantly greater than the same procedure in a previously untreated patient.
T rIE effectiveness of a transsphenoidal microsurgical approach in primary surgical management of pituitary tumors and other lesions in and about the seUa turcica is now well established. 9 ' 11"26' 3~ 46,65,67 No systematic analysis of the risks and benefits of transsphenoidal surgery as either secondary or tertiary management in patients with prior treatment has been published. Previous analyses of the results and complications of transsphenoidal surgery 12,j5'2~ [40] [41] [42] [43] 49, 50, 57, 59, 65, 67 have tended to include all patients, regardless of whether they had received therapy prior to the transsphenoidal operation. Pertinent information gleaned from these published reports and from our own experience suggests that results are less satisfactory and risks are higher in those patients who have undergone unsuccessful prior treatment. It is the goal of this report to quantify results and complications in this group of patients with challenging problems of surgical management.
Clinical Material and Methods
The case records of all Mayo Clinic patients who were treated by transsphenoidal microsurgery in a lOyear period ending in June, 1983, were reviewed. Of the 1210 patients so treated, 158 (13%) had received prior therapy. Their records were reviewed in detail and current follow-up data were obtained. No patient was lost to follow-up review. The mean follow-up period was 37 months. The specific entities treated and the prior management are summarized in Tables 1 and 2 . Data on each patient were recorded on a standard form and were analyzed by computer.
Prior therapy was considered "direct" when it consisted of craniotomy or transsphenoidal surgery (either open or stereotaxic), with some cases having adjunctive radiotherapy to the pituitary region. Prior therapy was considered "indirect" when it consisted of radiotherapy alone, adrenalectomy, or medical therapy with bromocriptine or adrenal toxins. direct approach  craniotomy  0  3  0  0  1  7  11  transsphenoidal surgery  5  8  1  0  1  3  18  stereotaxic RF  2  0  0 "  0  0  0  2  craniotomy & RT  2  6  0  0  2  19  29  transsphenoidal surgery & RT  0  1  1  0  0  3  5  indirect approach  RT only  4  5  1  0  0  1  11  adrenalectomy  0  0  0  16  0  0  16  bromocriptine  0  20  0  0  0  0  20  other combinations  0  4  1  8  1  1  15  total cases  13  47  4  24  5  34  127 * LH/FSH = luteinizing hormone/follicle stimulating hormone; RF = radiofrequency thermocoagulation; RT = radiation therapy.
Results
The rationale for secondary transsphenoidal surgery was separable into several major categories (Table 3) . The most important category was that of patients with persistent or recurrent sellar neoplasms presenting with mass effect, usually progressive visual loss. The second largest group included endocrine-active pituitary adenomas with persistent or recurrent hyperfunctioning pituitary endocrine syndromes: acromegaly, hyperprolactinemia, Cushing's disease, or Nelson's syndrome. The third largest category included patients with cerebrospinal fluid (CSF) rhinorrhea, usually as a complication of a prior transsphenoidal operation.
Prior management included surgery (craniotomy, transsphenoidal surgery, or adrenalectomy) with and without adjunctive radiation therapy (Tables 1 and 2 ). A few patients had been managed with stereotaxic radiofrequency thermocoagulation. A large group had been treated by radiotherapy only, usually with cobalt- 60 or a linear accelerator, and a few with the proton beam. A group of patients with prolactinomas had been treated medically with bromocriptine, 6m63 and most of these had responded suboptimally or had developed adverse reactions.
The success rate for each of the endocrine-active syndromes is detailed in Table 4 , with a separate analysis of those patients for whom the primary indication for transsphenoidal surgery was persistent hypersecretion of a pituitary hormone. The results with regard to resolution of mass effect as measured by visual function are given in Table 5 . Table 6 presents the incidence of new problems or complications that occurred after transsphenoidal sur- 
arachnoid cyst other lesions ----
* CSF = cerebrospinal fluid; ACTH = adrenocorticotropic hormone; LH/FSH = luteinizing hormone/follicle-stimulating hormone; --= indication not present.
t Some of these patients also had pituitary hyperfunction. gery in these patients. Tables 7 and 8 give the subsequent therapy needed and the overall outcome on follow-up examination, providing some indication of the quality of survival following surgery.
As noted in Table 3 , CSF rhinorrhea was the primary indication for surgery in 21 patients. Successful repair of the rhinorrhea was accomplished in 16 (76%). Subsequent attempts at management of CSF rhinorrhea included another transsphenoidal approach (one patient), transethmoidal repair (two patients), craniotomy (one patient), and CSF shunt (one patient). Despite this, CSF rhinorrhea persists in two of these five patients.
Discussion
In the endocrine-active syndromes, the decision to intervene surgically when prior therapy has been ineffective is not made lightly. Patients who have failed to be controlled by previous attempts at management represent a refractory group in which excellent results rarely occur after another attempt, no matter how skilled the surgeon. Indications for transsphenoidal sur- gery in these patients include several different situations. The first is clear evidence (usually radiographic) that prior therapy has been inadequately or inexpertly performed. In this category are patients whose initial surgery was not completed because of intraoperative technical difficulties or complications such as excessive bleeding. Also included are patients in whom the computerized tomography scan shows a significant volume of readily accessible residual tumor; many patients managed primarily by radiation therapy or dopamine agonist therapy are in this category. Patients who were apparently "cured" following primary management and later develop progressive pathological increases of hormone secretion may also be candidates for transsphe- noidal exploration when they have evidence of surgically accessible recurrent tumor.
Patients with clinical evidence of mass effect persisting or recurring after primary therapy may be suitable candidates for transsphenoidal decompression. A few patients who develop visual loss presumed to be due to prolapse of the optic apparatus into an empty sella 52"64"66 may benefit from transsphenoidal surgery. These attempts carry some risk, however, as adhesions and the tenuous nature of the chiasmal blood supply may result in deterioration rather than improvement of vision following the packing of an empty sella.
Cerebrospinal fluid rhinorrhea in patients with pituitary tumors may occur spontaneously, ~~ may follow radiation or drug therapy, 2 or may be a complication of transcranial, transsphenoidal, or stereotaxic surgery. 34' 38 Both the transseptal transsphenoidal and transethmoidal transsphenoidal approaches may be useful in repairing these CSF leaks. 8'33'34 When they occur immediately after a standard transseptal operation, prompt reexploration using the same approach is usually successful. All of the iatrogenic cases in this report were managed successfully with this method. Patients with delayed CSF leaks and those with rhinorrhea following irradiation and/or drug therapy (usually those with invasive tumors) respond best to a transethmoidal transsphenoidal repair. Cerebrospinal fluid leaks following craniotomy for pituitary tumor can usually be managed by an extracranial approach, but will require craniotomy if the extracranial attempt fails.
There are numerous important differences between the patient whose prior therapy has failed and the more typical patient treated primarily by transsphenoidal surgery. The former group is older (mean age 42 years), includes a higher proportion of males (51%), has a much higher proportion of large tumors (85% larger than 10 mm in diameter), and has more tumors with suprasellar (51%) or lateral (16%) extension.
As anticipated, the results with regard to control of hyperfunctioning endocrine syndromes are less satisfactory in previously treated patients. In acromegaly, where a success rate between 65% and 70% may be anticipated in patients treated primarily by transsphenoidal surgery, 4, 5, 13, [21] [22] [23] 32, 39, 44, 45, 48, 53, 65, 67 the patients in the study group had a successful outcome in 56% of cases. In prolactinomas, where success rates between 66% and 88% have been reported with primary treatmeat, 1"3"14' 18' 24' 29' 31' 36' 37' 40' 43' 51' 54' 55' 58' 65,67 only 36% of the study group had a successful outcome. Instead of an 80% primary treatment success rate in Cushing's disease,6,7,~ 7,28,35.40.56,61.65,67 only 2 5 % were controlled at secondary therapy, and the results were similarly affected in Nelson's syndrome. 28,4~ Reports of visual recovery following transsphenoidal decompression of sellar and suprasellar lesions indicate an anticipated success rate of 80% to 86%. 16,19.47,60 Previously treated patients were less likely to experience an improvement or return to normal of visual fields (59%).
The difficult nature of this group of clinical problems is underscored by the fact that 75 of the 154 surviving patients required some form of subsequent therapy (Table 7) . Patients with unsatisfactory control of hypersecreting syndromes were treated with radiation therapy or bromocriptine whenever possible. Among the patients with prolactin-secreting adenomas, six had subsequent radiotherapy, 29 received bromocriptine, and two had both. Many of these patients had previously been refractory to or intolerant of bromocriptine, and ultimate normalization of prolactin was achieved in only 29%. Recurrent symptomatic tumors required subsequent surgery in two patients with prolactin macroadenomas, in two patients with acromegaly (one with a microadenoma initially and one with a diffuse tumor having a nodular suprasellar extension), in one patient with Cushing's disease who had a microadenoma initially, and in six patients with Nelson's syndrome and tumors of various sizes. This additional surgery normalized excess hormone secretion in both acromegaly patients and in the patient with Cushing's disease, but did not do so in the others.
Postoperative radiation therapy was given whenever possible in cases of persistent acromegaly (one case) and Nelson's syndrome (five cases). Postoperative radiation therapy is generally recommended for patients with large null-cell or gonadotropic adenomas having suprasellar extension, and was given to I I of these patients who had not previously been so treated. The goal in these cases is to lower the late recurrence rate. In cases of craniopharyngioma, where incomplete excision for palliation was the rule, postoperative radiation was given whenever possible (four cases). Because of the frequency of recurrence, three of the patients required subsequent surgery for tumor removal. Two patients developed CSF leaks after radical removal of craniopharyngiomas and were successfully managed with a prompt transsphenoidal reexploration.
Complications were most frequent and most serious in patients with prior craniotomy. Postoperative changes in the form of scarring, adhesions, unusual vascularity, and distortions of normal anatomy add significantly to the hazards of repeat surgery. The same factors are present in patients who have previously been treated by transsphenoidal surgery, but are usually less of a problem. Reconstruction of the sellar floor may be particularly challenging because of loss of the bone borders of the sella and lack of nasal septal bone or cartilage. Complications relating to the nose and sinuses are more frequent in this group as well.
Prior radiation therapy may produce secondary changes, including thinning of the bone at the base of the skull, and may predispose to postoperative CSF leaks, but it is virtually never a contraindication to transsphenoidal surgery. Irradiation alone does not produce consistent changes in the nature of tumor tissue and does not usually make removal of the tumor significantly more difficult or hazardous. Prior bromocriptine therapy has been alleged to produce fibrosis within tumor tissue and to mitigate against postoperative normalization of prolactin secretion. 37 This change has been observed, but not consistently, and should not discourage an attempt at thorough transsphenoidal surgery. Prior adrenalectomy can make the perioperative management and hormone replacement therapy of patients with pituitary adenomas more difficult, but with careful attention to basic principles, 46 no complications developed in this group of patients.
Operative death occurred in four patients. One patient underwent transsphenoidal hypophysectomy for metastatic carcinoma, had an immediate postoperative CSF leak, and died of meningitis after an unsuccessful transsphenoidal operation to repair the leak. The three other operative deaths occurred in patients with prior craniotomy and radiotherapy for pituitary adenoma (two null-cell and one prolactin-secreting adenoma), and were related to hemorrhage in two cases and hypothalamic damage in the third. Late deaths occurred in four patients. Two patients had pituitary adenomas which behaved in a locally malignant fashion, and died of tumor progression. Late deaths were related to subsequent surgical management in the two other patients: one patient with a chordoma died following a craniotomy 3 years later, and one with a craniopharyngioma died following another transsphenoidal operation 2 years later.
Major morbidity was also related to prior craniotomy (Table 6 ). A patient with stroke (carotid spasm) and one with a vascular injury (anterior cerebral artery) had been treated by prior craniotomy and radiotherapy. A patient with a sixth nerve palsy had been treated by prior transsphenoidal surgery, radiotherapy, and bromocriptine. Two patients had meningitis following postoperative CSF rhinorrhea: one was fatal and the other responded to antibiotic therapy and repair of the CSF leak.
These patients with failed prior therapy are a select group, and it would be improper to make generalized conclusions with regard to the management of pituitary adenomas from these results. However, they do emphasize some of the challenges of pituitary surgery. We continue to face the problems of invasive tumors refractory to endocrine cure, late recurrence of cleanly removed pituitary adenomas and craniopharyngiomas, and the management of iatrogenic complications of therapy for these lesions.
Conclusions
It is evident that the risks in patients subjected to secondary transsphenoidal surgery are higher than in patients who had received no prior therapy. Two-thirds of the operative deaths in our series of transsphenoidal operations occurred in this group of patients. In addition, serious complications, such as arterial injuries, cranial nerve damage, and iatrogenic visual loss, are all more frequent following transsphenoidal surgery in patients in whom prior attempts at management have failed.
On the other hand, careful transsphenoidal surgery, when indicated, can lead to impressive salvage in a number of difficult clinical situations. Hyperfunctioning endocrine syndromes can be normalized in 25% to 56% of cases, progressive loss of vision can be halted and vision improved in 60%, and CSF leaks can be effectively repaired in more than 70%. Additional emphasis on accurate patient selection and improvements in technique should lead to even better results in the future.
